Nashville Early Diagnosis Lung Cancer Project
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 55 - 80 |
| Updated: | 5/3/2018 |
| Start Date: | April 2011 |
| End Date: | November 30, 2022 |
| Contact: | Vanderbilt-Ingram Service for Timely Access |
| Phone: | 800-811-8480 |
This screening study will address the lack of molecular strategies for the early detection of
lung cancer and integrate those with epidemiological and imaging strategies.
The hypothesis is that the repeated measure of biomarkers of risk obtained from the molecular
analysis of biological specimens including those from bronchoscopy (bronchial brushings and
biopsies) may contribute to the refinement of high-risk populations and allow an earlier
clinical diagnosis.
The goal of the investigators study is to provide screening for lung cancer in a high-risk
population. In this prospective cohort it will be tested whether repeated measure of
biomarkers of risk allows early detection of lung cancer.
lung cancer and integrate those with epidemiological and imaging strategies.
The hypothesis is that the repeated measure of biomarkers of risk obtained from the molecular
analysis of biological specimens including those from bronchoscopy (bronchial brushings and
biopsies) may contribute to the refinement of high-risk populations and allow an earlier
clinical diagnosis.
The goal of the investigators study is to provide screening for lung cancer in a high-risk
population. In this prospective cohort it will be tested whether repeated measure of
biomarkers of risk allows early detection of lung cancer.
It is proposed to test the hypotheses in a screening study of high risk individuals
(characterized by an established prediction rule). The expected prevalence of lung cancer in
this high risk group is estimated to be 2% per year. All individuals benefit from clinic
visit, low-dose Chest CT, spirometry and auto-fluorescence bronchoscopy at baseline, Chest
CT, follow-up doctor visit, and auto-fluorescence bronchoscopy at least at year 2 and 5.
(characterized by an established prediction rule). The expected prevalence of lung cancer in
this high risk group is estimated to be 2% per year. All individuals benefit from clinic
visit, low-dose Chest CT, spirometry and auto-fluorescence bronchoscopy at baseline, Chest
CT, follow-up doctor visit, and auto-fluorescence bronchoscopy at least at year 2 and 5.
Inclusion Criteria:
- 55 - 80 years of age
- Current smoker or former smoker. If former smoker, must have quit smoking less than 15
years ago
- >/= 30 pack year of smoking history
Exclusion Criteria:
- History of diagnosis/treatment of lung cancer in the past 2 years
- History of head/neck or esophageal cancer in the last 1 year
- Inability to provide informed consent
- Participants in whom stopping anti-platelet or anti-coagulation therapy would have an
adverse effect (DVT, mechanical heart valves, unstable coronary syndrome, etc.)
We found this trial at
3
sites
Nashville, Tennessee 37232
Principal Investigator: Pierre P Massion, MD
Phone: 800-811-8480
Click here to add this to my saved trials
Nashville, Tennessee 37212
Principal Investigator: Pierre P Massion, MD
Phone: 615-875-6099
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Pierre P Massion, MD
Phone: 800-811-8480
Click here to add this to my saved trials